Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.65 |
| ▸ | JAK3 | P52333 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16405547 | 0.91 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL17498519 | 0.91 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL19100056 | 0.90 | EGFR (0.89) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL21761366 | 0.89 | EGFR (0.84) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL19100271 | 0.89 | EGFR (0.71) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL16398696 | 0.88 | EGFR (0.79) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL16398699 | 0.88 | EGFR (0.79) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL19100301 | 0.88 | EGFR (0.85) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL19125881 | 0.88 | EGFR (0.58) | EGFRERBB2 | |
| SCHEMBL19100300 | 0.88 | EGFR (0.73) | EGFRERBB2ERBB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
| WO-2017117680-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885ERBB4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.